137 related articles for article (PubMed ID: 24334256)
1. Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.
Ferenci P; Dusheiko G
Gut; 2014 Jul; 63(7):1033-4. PubMed ID: 24334256
[No Abstract] [Full Text] [Related]
2. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
Zeuzem S
J Hepatol; 2008 Aug; 49(2):157-9. PubMed ID: 18554745
[No Abstract] [Full Text] [Related]
3. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
4. Controlling hepatitis C with simeprevir.
Dusheiko G
Lancet Infect Dis; 2015 Jan; 15(1):2-4. PubMed ID: 25482331
[No Abstract] [Full Text] [Related]
5. Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.
Wiegand J; Maasoumy B; Buggisch P; Buslau A; Schiefke I; Berg T; Wedemeyer H; Sarrazin C; Hinrichsen H
Aliment Pharmacol Ther; 2014 Jun; 39(11):1342-4. PubMed ID: 24803258
[No Abstract] [Full Text] [Related]
6. Difficult management of triple therapy for chronic hepatitis C in a patient on haemodialysis.
Plana L; Peño L; Urquijo JJ; Diago M
Gastroenterol Hepatol; 2017 May; 40(5):356-358. PubMed ID: 27048917
[No Abstract] [Full Text] [Related]
7. Chronic hepatitis C successfully treated with telaprevir, pegylated interferon and ribavirin in severe aplastic anemia.
Balkan II; Bozcan S; Yemisen M; Kutlubay Z; Ozaras R
Ann Hepatol; 2014; 13(6):843-4. PubMed ID: 25332274
[No Abstract] [Full Text] [Related]
8. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
Ogawa E; Furusyo N; Dohmen K; Kajiwara E; Kawano A; Nomura H; Takahashi K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J;
J Viral Hepat; 2015 Dec; 22(12):992-1001. PubMed ID: 26075320
[TBL] [Abstract][Full Text] [Related]
9. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
Dusheiko G; Wedemeyer H
Gut; 2012 Dec; 61(12):1647-52. PubMed ID: 22936671
[No Abstract] [Full Text] [Related]
10. [Therapy of chronic hepatitis C].
Schaffstein S; Rampini SK; Müllhaupt B
Praxis (Bern 1994); 2014 Apr; 103(8):423-36. PubMed ID: 24713377
[No Abstract] [Full Text] [Related]
11. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
12. ADVANCE study begins enrollment.
AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
[No Abstract] [Full Text] [Related]
13. [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
Virolés Torrent S; López Nuñez C; Hombrados Verde M; Figa Francesch M; Ferri Iglesias MJ; Louvriex Freire R; Acero Fernández D
Gastroenterol Hepatol; 2015 Feb; 38(2):78-81. PubMed ID: 24948444
[No Abstract] [Full Text] [Related]
14. [Treatment of chronic hepatitis viral C: new associations].
Ouzan D
Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659
[TBL] [Abstract][Full Text] [Related]
15. Comment on the PROVE1 and PROVE2 clinical trials: "I was taking a picture of Rapid Virological Response with telaprevir, but the background is unfocused!".
Baiocchi L; Lenci I; Carbone M; Angelico M
Hepatology; 2009 Nov; 50(5):1676-7. PubMed ID: 19876945
[No Abstract] [Full Text] [Related]
16. An overview of emerging therapies for the treatment of chronic hepatitis C.
Ilyas JA; Vierling JM
Clin Liver Dis; 2011 Aug; 15(3):515-36. PubMed ID: 21867934
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
; Coco B; Caraceni P; Aghemo A; Bitetto D; Bruno R; Ciancio A; Marzioni M; Petta S; Rendina M; Valenti L;
Dig Liver Dis; 2014 Jan; 46(1):18-24. PubMed ID: 24119482
[TBL] [Abstract][Full Text] [Related]
18. A step forward in therapy for hepatitis C.
Hoofnagle JH
N Engl J Med; 2009 Apr; 360(18):1899-901. PubMed ID: 19403908
[No Abstract] [Full Text] [Related]
19. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
Hadziyannis SJ; Sevastianos V
Aliment Pharmacol Ther; 2013 Feb; 37(4):491. PubMed ID: 23336678
[No Abstract] [Full Text] [Related]
20. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
Martínez-Bauer E; Forns X
Gastroenterol Hepatol; 2003 May; 26(5):303-6. PubMed ID: 12732104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
